Advertisement
Rapid Communication| Volume 89, P5-8, July 2016

Associations of androgens with health care utilization and costs in women—Perspectives of a population-based cohort study

      Highlights

      • This is the first large-scale population-based epidemiological-econometric study to employ sex hormone measurements from liquid chromatography-tandem mass spectrometry.
      • It is the first investigation of potential associations between sex hormones and health care utilization and costs in women.
      • Sex hormone-binding globulin correlated inversely and free testosterone positively with long-term health care costs.

      Abstract

      Objective

      Despite associations between total testosterone (TT) concentrations and increased cardiometabolic risk, the impact of serum androgens on health care utilization and costs among women is unknown.

      Methods

      We used data from 1521 women in the population-based cohort Study of Health in Pomerania (SHIP) to investigate the associations of serum TT (measured by liquid chromatography-tandem mass spectrometry), sex hormone-binding globulin (SHBG), and free testosterone (free T) with health care utilization and costs at baseline and five-year follow-up (N = 1210), implementing multivariable-adjusted econometric models.

      Results

      Cross-sectional analyses showed no association of TT, SHBG, or free T with hospitalization or total health costs (outpatient as well as inpatient costs). Prospective analyses revealed an inverse association of baseline SHBG with follow-up total health care costs (% change per standard deviation (SD): −26.2%, 95% confidence interval (CI): −42.2%; −8.9%) and inpatient costs (% change per SD: −26.5%%, 95% CI: −45.5%; −2.5%). Baseline free T was positively associated with total health care costs at the five-year follow-up (% change per SD: +37.7%, 95% CI: +4.6%; +81.4%).

      Conclusions

      In this first cost analysis among women from the general population, we observed no association of androgen serum concentration with health care utilization and costs. However, baseline SHBG appeared to be inversely correlated and free T positively correlated with long-term health care costs.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brand J.S.
        • van der Schouw Y.T.
        Testosterone, SHBG and cardiovascular health in postmenopausal women.
        Int. J. Impot. Res. 2010; 22: 91-104
        • Ding E.L.
        • Song Y.
        • Malik V.S.
        • Liu S.
        Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.
        JAMA. 2006; 295: 1288-1299
        • Brand J.S.
        • van der Tweel I.
        • Grobbee D.E.
        • Emmelot-Vonk M.H.
        • van der Schouw Y.T.
        Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies.
        Int. J. Epidemiol. 2011; 40: 189-207
        • Haring R.
        • Baumeister S.E.
        • Volzke H.
        • Kohlmann T.
        • Marschall P.
        • Flessa S.
        • Nauck M.
        • Wallaschofski H.
        Prospective association of low serum total testosterone levels with health care utilization and costs in a population-based cohort of men.
        Int. J. Androl. 2010; 33: 800-809
        • Volzke H.
        • Alte D.
        • Schmidt C.O.
        • Radke D.
        • Lorbeer R.
        • Friedrich N.
        • Aumann N.
        • Lau K.
        • Piontek M.
        • Born G.
        • Havemann C.
        • Ittermann T.
        • Schipf S.
        • Haring R.
        • Baumeister S.E.
        • Wallaschofski H.
        • Nauck M.
        • Frick S.
        • Arnold A.
        • Junger M.
        • Mayerle J.
        • Kraft M.
        • Lerch M.M.
        • Dorr M.
        • Reffelmann T.
        • Empen K.
        • Felix S.B.
        • Obst A.
        • Koch B.
        • Glaser S.
        • Ewert R.
        • Fietze I.
        • Penzel T.
        • Doren M.
        • Rathmann W.
        • Haerting J.
        • Hannemann M.
        • Ropcke J.
        • Schminke U.
        • Jurgens C.
        • Tost F.
        • Rettig R.
        • Kors J.A.
        • Ungerer S.
        • Hegenscheid K.
        • Kuhn J.P.
        • Kuhn J.
        • Hosten N.
        • Puls R.
        • Henke J.
        • Gloger O.
        • Teumer A.
        • Homuth G.
        • Volker U.
        • Schwahn C.
        • Holtfreter B.
        • Polzer I.
        • Kohlmann T.
        • Grabe H.J.
        • Rosskopf D.
        • Kroemer H.K.
        • Kocher T.
        • Biffar R.
        • John U.
        • Hoffmann W.
        Cohort profile: the study of health in pomerania.
        Int. J. Epidemiol. 2010;
        • Bock J.O.
        • Brettschneider C.
        • Seidl H.
        • Bowles D.
        • Holle R.
        • Greiner W.
        • Konig H.H.
        Calculation of standardised unit costs from a societal perspective for health economic evaluation.
        Gesundheitswesen. 2015; 77 (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)): 53-61
        • Krauth C.
        • Hessel F.
        • Hansmeier T.
        • Wasem J.
        • Seitz R.
        • Schweikert B.
        Empirical standard costs for health economic evaluation in Germany − a proposal by the working group methods in health economic evaluation.
        Gesundheitswesen. 2005; 67: 736-746
        • Haring R.
        • Hannemann A.
        • John U.
        • Radke D.
        • Nauck M.
        • Wallaschofski H.
        • Owen L.
        • Adaway J.
        • Keevil B.G.
        • Brabant G.
        Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry.
        J. Clin. Endocrinol. Metab. 2012; 97: 408-415
        • Vermeulen A.
        • Verdonck L.
        • Kaufman J.M.
        A critical evaluation of simple methods for the estimation of free testosterone in serum.
        J. Clin. Endocrinol. Metab. 1999; 84: 3666-3672
        • Mullahy J.
        Econometric modeling of health care costs and expenditures: a survey of analytical issues and related policy considerations.
        Med. Care. 2009; 47: S104-S108
        • White I.R.
        • Royston P.
        • Wood A.M.
        Multiple imputation using chained equations: issues and guidance for practice.
        Stat. Med. 2011; 30: 377-399
        • Xu H.
        • Daggy J.
        • Yu D.
        • Craig B.A.
        • Sands L.
        Joint modeling of medical cost and survival in complex sample surveys.
        Stat. Med. 2013; 32: 1509-1523
        • Laughlin G.A.
        • Goodell V.
        • Barrett-Connor E.
        Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women.
        J. Clin. Endocrinol. Metab. 2010; 95: 740-747
        • Worsley R.
        • Robinson P.J.
        • Bell R.J.
        • Moufarege A.
        • Davis S.R.
        Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women.
        Menopause (New York, N. Y.). 2013; 20: 640-645
        • Haring R.
        • Teumer A.
        • Volker U.
        • Dorr M.
        • Nauck M.
        • Biffar R.
        • Volzke H.
        • Baumeister S.E.
        • Wallaschofski H.
        Mendelian randomization suggests non-causal associations of testosterone with cardiometabolic risk factors and mortality.
        Andrology. 2013; 1: 17-23
        • Snabes M.C.
        • Simes S.M.
        Approved hormonal treatments for HSDD: an unmet medical need.
        J. Sex. Med. 2009; 6: 1846-1849
        • Bell R.J.
        • Davison S.L.
        • Papalia M.A.
        • McKenzie D.P.
        • Davis S.R.
        Endogenous androgen levels and cardiovascular risk profile in women across the adult life span.
        Menopause (New York, N. Y.). 2007; 14: 630-638
        • Davis S.R.
        • Robinson P.J.
        • Moufarege A.
        • Bell R.J.
        The contribution of SHBG to the variation in HOMA-IR is not dependent on endogenous oestrogen or androgen levels in postmenopausal women.
        Clin. Endocrinol. (Oxf.). 2012; 77: 541-547